Multidrug-resistant Candida auris is an urgent antimicrobial resistance threat and the key method of prevention is strict adherence to infection control measures.
Approximately 1 in 10 patients with candidemia had a history of recent injection drug use based on a surveillance program in the Denver metropolitan area.
Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible infection.
A recent microbiological surveillance study found that >10% of linens tested positive for the fungi Mucorales at 20% of the hospitals included in the study.
The Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic bone marrow transplantation is anticipated to start in the first quarter of 2019.
Screening of asymptomatic coccidioidomycosis within a Coccidioides-endemic area allowed for identifying and managing asymptomatic cases before patients began tumor necrosis factor-α inhibitor therapy.
A novel nanodiagnostic panel may be helpful in reducing the length of empiric antifungal treatment in patients with multiple risk factors for candidemia.
Based on the findings, it was concluded that fluconazole use during pregnancy was not associated with significantly increased risks of stillbirth or neonatal death. However, the authors cautioned that the confidence intervals were wide and neither result was statistically significant.
Although rare even in high-risk groups, invasive aspergillosis is associated with high hospital mortality rates, excess duration of hospitalization, and a 40% relative increase in the odds of 30-day readmission.
Results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of recurrent vulvovaginal candidiasis.
While isavuconazole is an important therapeutic option in the management of invasive fungal infections, the epidemiology and microbiology of breakthrough infections on this agent are not well understood.
